Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 6/2011

01.04.2011 | Adis Drug Profile

Sitafloxacin

In Bacterial Infections

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Sitafloxacin is a fluoroquinolone antibacterial with in vitro activity against a broad range of Grampositive and -negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. It is approved in Japan for use in a number of bacterial infections caused by sitafloxacin-susceptible strains of Staphylococcus spp., Streptococcus pneumoniae, other Streptococcus spp., Enterococcus spp., Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Enterobacter spp., Serratia spp., Proteus spp., Morganella morganii, Haemophilus influenzae, Pseudomonas aeruginosa, Legionella pneumophila, Peptostreptococcus spp., Prevotella spp., Porphyromonas spp., Fusobacterium spp., Chlamydia trachomatis, Chlamydophila pneumoniae and Mycoplasma pneumoniae.
In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, non-inferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials.
Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis- associated cervicitis in women and odontogenic infections.
Gastrointestinal disorders and laboratory abnormalities were the most commonly occurring adverse reactions in patients receiving oral sitafloxacin. Adverse reactions reported in sitafloxacin recipients in the active comparator trials were of mild to moderate severity.
Literatur
1.
Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009 Sep; 64 Suppl. 1: i3–10PubMedCrossRef
2.
Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother 2003 Dec; 9(4): 285–91PubMedCrossRef
3.
Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003 Dec; 52(6): 944–52PubMedCrossRef
4.
Yokota S, Sato K, Kuwahara O, et al. Fluoroquinoloneresistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002 Oct; 46(10): 3311–5PubMedCrossRef
5.
Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005 Dec; 116 (6 Suppl.): S13–47PubMedCrossRef
6.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1; 44 Suppl. 2: S27–72PubMedCrossRef
7.
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011 Mar 1; 52(5): e103–20PubMedCrossRef
8.
Albertson TE, Chan AL. Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis. Expert Rev Respir Med 2009 Oct; 3(5): 539–48PubMedCrossRef
9.
Yamaguchi K, Ohno A, Ishii Y, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007 [in Japanese]. Jpn J Antibiot 2009 Aug; 62(4): 346–70PubMed
10.
Daiichi Sankyo Co., Ltd. Gracevit® tablets 50 mg, fine granules 10%: prescribing information. Japan: 2009 Jun
11.
Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62(1): 13–59PubMedCrossRef
12.
Okumura R, Hirata T, Onodera Y, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quino-lone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008 Jul; 62(1): 98–104PubMedCrossRef
13.
Onodera Y, Uchida Y, Tanaka M, et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999 Oct; 44(4): 533–6PubMedCrossRef
14.
Morrissey I, George JT. Inhibition of pneumococcal topoisomerases by sitafloxacin. Drugs 1999; 58 Suppl. 2: 354–5CrossRef
15.
Tanaka M, Onodera Y, Uchida Y, et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997 Nov; 41(11): 2362–6PubMed
16.
Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994 Nov; 38(11): 2623–7PubMedCrossRef
17.
Amano A, Matsuzaki K, Kishi N, et al. In vitro activity of sitafloxacin against clinical isolates in 2009 [in Japanese]. Jpn J Antibiot 2010 Dec; 63(6): 411–30PubMed
18.
Kanda H, Kurosaka Y, Fujikawa K, et al. In vitro and in vivo antibacterial activity of sitafloxacin [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 1–17
19.
Yamamoto N, Fujita J, Shinzato T, et al. In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus. Int J Antimicrob Agents 2006 Feb; 27(2): 171–3PubMedCrossRef
20.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2008
21.
Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis 2009 Sep; 65(1): 76–80PubMedCrossRef
22.
Giamarellou-Bourboulis EJ, Sambatakou H, Grecka P, et al. Sitafloxacin (DU-6859a) and trovafloxacin: post-antibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1999 Aug; 34(4): 301–7PubMedCrossRef
23.
Mikamo H, Kawazoe K, Sato Y, et al. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. J Antimicrob Chemother 1998 Jan; 41(1): 131–3PubMedCrossRef
24.
Fukuda Y, Yanagihara K, Ohno H, et al. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrob Agents Chemother 2006 Jan; 50(1): 121–5PubMedCrossRef
25.
Nakamura S, Yanagihara K, Araki N, et al. In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube. Int J Antimicrob Agents 2009 Sep; 34(3): 210–4PubMedCrossRef
26.
Kurosaka Y, Ishida Y, Yamamura E, et al. Therapeutic efficacy of sitafloxacin against Pseudomonas aeruginosa in a rat model of urinary tract infection. Drugs 1999; 58 Suppl. 2: 412–4CrossRef
27.
Hong SG, Moland ES, Wickman PA, et al. In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in Gram-positive cocci. Antimicrob Agents Chemother 2007 Apr; 51(4): 1512–4PubMedCrossRef
28.
Touyama M, Higa F, Nakasone C, et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 2006 Dec; 58(6): 1279–82PubMedCrossRef
29.
Saito A, Watanabe A, Aoki N, et al. Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 49–62
30.
Hori S, Kobayashi H, Saito A, et al. Clinical trials of sitafloxacin (DU-6859a): clinical safety profile [abstract no. L-489 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
31.
Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995 Jan; 39(1): 170–4PubMedCrossRef
32.
Saito A, Tanigawara Y, Watanabe A, et al. Open study of sitafloxacin in patients with respiratory tract infections: PK/PD study [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 63–80
33.
Sasaki J, Hori S. Oral tissue distribution, efficacy, and safety of sitafloxacin in patients with dentistry and oral surgery infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 121–9
34.
Baba S, Suzuki K, Yamanaka N, et al. Efficacy and safety of sitafloxacin in patients with otorhinolaryngological infections and its tissue distribution in the otorhinolaryngological field [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 110–20
35.
O’Grady J, Briggs A, Atarashi S, et al. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoro-quinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 2001 Nov; 31(11): 811–22PubMedCrossRef
36.
Payne GS, Collins DJ, Loynds P, et al. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo 19F magnetic resonance spectroscopy. Br J Clin Pharmacol 2005 Feb; 59(2): 244–8PubMedCrossRef
37.
Nakashima M. Pharmacokinetics of sitafloxacin (DU-6859a) in healthy volunteers [in Japanese]. Jpn J Chemother 2008; 56 Suppl. 1: 154–5
38.
Nakashima M, Kawada Y. Pharmacokinetic profiles of sitafloxacin in patients with renal dysfunction [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 21–4
39.
Sekino H. Pharmacokinetic profiles of sitafloxacin in elderly volunteers [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 18–20
40.
Shiba K. Effect of ranitidine on sitafloxacin absorption [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 32–5
41.
Shiba K. Effect of metal-ion on sitafloxacin absorption [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 25–31
42.
Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother 1998 Jul; 42(7): 1751–5PubMed
43.
MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoro-quinolone dosing regimens. J Antimicrob Chemother 2000 Aug; 46(2): 163–70PubMedCrossRef
44.
Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003 Apr; 22(4): 203–21PubMed
45.
Kobayashi H, Watanabe A, Nakata K, et al. Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 36–48
46.
Kawada Y, Yasuda M, Tanaka K, et al. Dose-comparative study of sitafloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 92–102
47.
Kawada Y, Ishihara S, Matsui T, et al. Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 81–91
48.
Kawada Y, Matsumoto T, Onodera S, et al. Clinical study of sitafloxacin in male nongonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 130–8
49.
Onodera S, Hori S. Clinical study of sitafloxacin in the treatment of male gonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 146–53
50.
Matsuda S, Noguchi M, Yasuda J, et al. Clinical study of sitafloxacin in treatment of cervicitis with Chlamydia trachomatis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 139–45
51.
Dawe RS, Ibbotson SH, Sanderson JB, et al. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol 2003 Dec; 149(6): 1232–41PubMedCrossRef
52.
Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 2008 Jul; 44(7): 489–501CrossRef
Metadaten
Titel
Sitafloxacin
In Bacterial Infections
verfasst von
Gillian M. Keating
Publikationsdatum
01.04.2011
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 6/2011
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11207380-000000000-00000

Weitere Artikel der Ausgabe 6/2011

Drugs 6/2011 Zur Ausgabe

Erratum

Erratum to Oral bepotastine in allergic disorders

Review Article

Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis

Adis Drug Evaluation

Lenograstim

Therapy in Practice

Fluoroquinolones in Community-Acquired Pneumonia

Adis Drug Evaluation

Telmisartan

Current Opinion

European Surveillance of Antimicrobial Consumption (ESAC)